All Photos(1)

Documents

COO/COA

G8048

GLP-1R agonist

Name: GLP-1R agonist
Brand: SIGMA

≥98% (HPLC), powder, glucose homeostasis regulator

Synonym(s):

2-Quinoxalinamine, 6,7-dichloro-N-(1,1-dimethylethyl)-3-(methylsulfonyl)-, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), Compound 2

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₃H₁₅Cl₂N₃O₂S

CAS Number:

281209-71-0

Molecular Weight:

348.25

UNSPSC Code:

12352200

NACRES:

NA.77

product name

GLP-1R agonist, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

light brown-yellow

solubility

DMSO: ≥10 mg/mL

storage temp.

2-8°C

InChI

1S/C13H15Cl2N3O2S/c1-13(2,3)18-11-12(21(4,19)20)17-10-6-8(15)7(14)5-9(10)16-11/h5-6H,1-4H3,(H,16,18)

InChI key

GNZCSGYHILBXLL-UHFFFAOYSA-N

General description

Glucagon-like peptide-1 receptor (GLP-1R) agonist is a potential oral drug for modulating glucagon-like peptide (GLP)-1 in diabetic patients. GLP-1R agonists play a key role in lowering glycated hemoglobin levels. It improves glycemic control and maintenance of body weight.

Biochem/physiol Actions

GLP-1R is a small molecule GLP-1 receptor agonist. GLP-1 receptor signaling is a predominant mechanism for regulating glucose homeostasis. This compound represents a unique non-peptide tool for studying the role of GLP-1 in both in vivo and in vitro diabetes and obesity models.

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover.

Juliana de F Germano et al.

Scientific reports, 10(1), 8284-8284 (2020-05-20)

Given that adverse remodeling is the leading cause of heart failure and death in the USA, there is an urgent unmet need to develop new methods in dealing with this devastating disease. Here we evaluated the efficacy of a short-course

GLP-1 receptor agonists: a review of head-to-head clinical studies.

Trujillo JM, et al.

Therapeutic advances in endocrinology and metabolism, 6(1), 19-28 (2015)

Proteomics of Mouse Heart Ventricles Reveals Mitochondria and Metabolism as Major Targets of a Post-Infarction Short-Acting GLP1Ra-Therapy.

Juliana de Freitas Germano et al.

International journal of molecular sciences, 22(16) (2021-08-28)

Cardiovascular disease is the main cause of death worldwide, making it crucial to search for new therapies to mitigate major adverse cardiac events (MACEs) after a cardiac ischemic episode. Drugs in the class of the glucagon-like peptide-1 receptor agonists (GLP1Ra)

Small-molecule agonists for the glucagon-like peptide 1 receptor.

Knudsen LB, et al.

Proceedings of the National Academy of Sciences of the USA, 104(3), 937-942 (2007)

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.

Garber AJ.

Diabetes Care, 34(Supplement 2), S279-S284 (2011)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service